Andexanet alfa for oral fxa inhibitor-associated major acute intracerebral hemorrhage: insights into clinically relevant thromboembolic events from the ANNEXA-I study
Saved in:
| Main Authors: | Mateo Porres-Aguilar, Luis Antonio Meillon-Garcia, João Carlos de Campos Guerra |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)
2025-01-01
|
| Series: | Jornal Vascular Brasileiro |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492024000100201&lng=en&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
165 An Analysis of the Use of Andexanet Alfa at the University of Utah Hospital
by: James R. Gustat, et al.
Published: (2025-05-01) -
Andexanet alfa: trials just leave us with more questions
by: Richard J. Buka
Published: (2025-01-01) -
Fibroxantoma Atípico (FXA)
by: Mónica Gaviria, et al.
Published: (2019-07-01) -
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality
by: Huiqiao Fan, et al.
Published: (2025-01-01) -
Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding
by: Alexander T. Cohen, et al.
Published: (2022-04-01)